Xencor (XNCR) Net earnings per share growth forecast for next year

Symbol and logo of brand Xencor Corp (XNCR)

This EPS growth analyst estimate chart illustrates the dynamics of market expectations, where the -47.60 mark serves as the current indicator. The financial stability of Xencor, Inc. (XNCR) is supported by licensing fees from partners that offset development costs. However, success depends on the outcome of clinical trials and R&D expenditures. Additional risks involve the potential emergence of more affordable therapies and the erosion of patent value.

XNCR - Xencor Corp Earnings growth forecast for next year over the range 07/04/2022 - 11/15/2026

Metric breakdowns and analytics for Xencor Corp (XNCR)

- price and consensus price forecast:
Analysis of all company metrics:Xencor Corp
Core merchandise of Xencor Inc

This indicator measures the analysts' consensus forecast for changes in earnings per share, stripping market expectations of corporate optimism through a daily revaluation of fundamental data. The current value of -47.60 reflects the balance between R&D costs and revenues from the XmAb platform; therefore, the forward EPS dynamics model for Xencor, Inc. (XNCR) serves as a signal of institutional readiness to invest in the future catalysts of Xencor, Inc. (XNCR).

Direct competitors

Net earnings per share growth forecast for next year immunitybio.com|Expected earnings per share growth for next year immunocore.com (IMCR)|Net earnings per share growth forecast for next year Janux Therapeutics Inc (JANX)|Expected earnings per share growth for next year Arcus Bio RCUS|Zymeworks Inc - Expected earnings per share growth for next year|Earnings growth forecast for next year Tango Therapeutics Corp TNGX|IOVA - Net earnings per share growth forecast for next year|IMTX (immatics.com) - Projected earnings per share growth rate for next year|Compass Therapeutics Corp (CMPX) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Replimune Corp (REPL)|Expected earnings per share growth for next year LYEL|IPHA - Net earnings per one share growth forecast for next year|Expected earnings per share growth for next year PYXS (Pyxis Oncology, Inc.)|Projected earnings per share increase next year CGEN|Earnings growth forecast for next year IOBT (IO Biotech)|Expected earnings per share trend next year STRO|minktherapeutics.com - Earnings growth forecast for next year|Expected net earnings per share growth next year Werewolf Therapeutics, Inc.|Immix (IMMX) - Net earnings per share growth forecast for next year|ALX Oncology Holdings - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Cue Biopharma|Earnings growth forecast for next year pdsbiotech.com|Net earnings per share growth forecast for next year sonnetbio.com (SONN)|MAIA: Net earnings per share change forecast for next year|Liminatus Pharma Inc. - Expected earnings per share growth for next year|LAVA Therapeutics N.V. (LVTX) - Expected net earnings per share growth next year|NXTC - Net earnings per share growth forecast for next year|LPTX: Net earnings per share growth forecast for next year|Intensity Therapeutics (INTS) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Sensei Bio (SNSE)|TOVX (Theriva Biologics Inc) - Earnings growth forecast for next year|Gritstone bio (GRTS) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year KA|Consensus forecast of earnings per share growth for next year NexImmune Inc|Net earnings per share growth forecast for next year turnstonebio.com TSBX|Consensus forecast of earnings per share growth for next year Vaccinex Inc (VCNX)|HARP - Net earnings per share growth forecast for next year